Laboratorios Atral

Laboratorios Atral

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Laboratorios Atral is an established, private Portuguese pharmaceutical firm with a dual business model encompassing proprietary product commercialization and contract services. The company has a historical legacy in antibiotic production and now maintains a portfolio of branded generic and specialty medicines, primarily in ophthalmology and dermatology. Its strategic focus includes expanding its service offerings as a CDMO and leveraging its regulatory expertise to commercialize products across Europe, Latin America, the Middle East, and Africa. Atral's operations are underpinned by a full-spectrum in-house infrastructure covering R&D, production, quality control, and pharmacovigilance.

OphthalmologyDermatology

Technology Platform

Integrated pharmaceutical development and manufacturing service platform, including GMP production, regulatory affairs, pharmacovigilance, and quality control for solid and semi-solid dosage forms.

Opportunities

Significant growth in the global CDMO market provides a major opportunity to expand its contract service business.
Its strong regulatory expertise in emerging markets (Latin America, Middle East, Africa) offers a distinct competitive advantage for clients seeking broad geographic commercialization support.

Risk Factors

Faces intense competition and pricing pressure in both the generic drug and CDMO sectors.
Operational risks include regulatory compliance across multiple jurisdictions and potential geopolitical or economic instability in its target export and service regions.

Competitive Landscape

In proprietary products, Atral competes with other generic and specialty pharma companies in Portugal and internationally. In CDMO services, it competes with a range of organizations from large global CDMOs to smaller regional manufacturers, differentiating itself through full-service integration and specific regulatory market expertise.